Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2005

View Archived Issues

Xcytrin with radiosurgery studied in phase II trial for brain metastases

Multi-party collaboration to develop treatments for spinal injury, neurotrauma

NexMed licenses NM-100060 for onychomycosis to Novartis

NicOx and Ferrer expand agreement in dermatology

Preliminary phase I data on VX-001 immunotherapy in cancer patients

Antidiabetic potential of RWJ-348260 evident in preclinical models

(-)-Oleocanthal, a compound in extra-virgin olive oil with ibuprofen-like activity

Preclinical profile and efficacy of CK-1827452 in a model of heart failure

Pharmacokinetics of oral insulin analogue IN-105 resemble those of insulin

KOS-2187: Novel motilide chosen as a clinical candidate

Novel NS5B polymerase inhibitor with in vitro efficacy and in vivo bioavailability

New efforts in avian flu vaccine development

Ziopharm and Easyweb complete merger

Hana Biosciences: pipeline progress

EntreMed enters CRADA with NCI to study HIF-1alpha inhibition in cancer

Cholesterol absorption inhibitor MD-0727 enters phase I testing

Prostaglandin F2alpha antagonist THG-113.31 delays preterm birth in sheep

Interim results for phase II study of Campath in MS

Affiris reports positive preclinical findings for Alzheimer's vaccine

rhGAD65 DNA vaccine prevents insulitis, beta cell apoptosis and diabetes onset in NOD mice

PSN-9301 in combination with metformin improves glucose tolerance in two rat models of diabetes

Remicade now approved in U.S. for ulcerative colitis

New data on the efficacy and safety of indacaterol in asthma and COPD

Recent patents describe new analgesic agents

Novel anti-HIV agents reported by Kumamoto

Agents for thrombotic disorders in early development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...